Dr. Smith quoted in recent article in the Alzheimer's Research Forum about using stem cell-based screening method to model ALS.

Lancet Neurology publishes landmark paper of a potential therapy for ALS developed in collaboration with UCSD and Isis Pharmaceutical Co: "An Antisense Oligonucleotide against SOD1 Delivered Intrathecally for Patients with SOD1-Familial Amyotrophic Lateral Sclerosis: a phase 1, randomized, first-in man study."

Dr. Smith counseled an ALS patient in Guatemala using Skype.